Pibrentasvir - Misplaced Pages

NS5A inhibitor antiviral agent Pharmaceutical compound

Pibrentasvir
Clinical data

Trade names	Mavyret, Maviret (combination with glecaprevir)
Other names	ABT-530
Pharmacokinetic data
Protein binding	>99.9%
Elimination half-life	13 hours
Excretion	96.6% in faeces
Identifiers
IUPAC name Methyl {(2S,3R)-1-phenyl}-5-(6-fluoro-2-{(2S)-1--2-pyrrolidinyl}-1H-benzimidazol-5-yl)-2-pyrrolidinyl]-6-fluoro-1H-benzimidazol-2-yl}-1-pyrrolidinyl]-3-methoxy-1-oxo-2-butanyl}carbamate
CAS Number	1353900-92-1
PubChem CID	58031952
DrugBank	DB13878
ChemSpider	35013016
UNII	2WU922TK3L
KEGG	D10816
Chemical and physical data
Formula	C₅₇H₆₅F₅N₁₀O₈
Molar mass	1113.201 g·mol
3D model (JSmol)	Interactive image
SMILES C((C(=O)N1CCC1c2c3cc(c(cc3n2)4CC(N4c5cc(c(c(c5)F)N6CCC(CC6)c7ccc(cc7)F)F)c8cc9c(cc8F)c(n9)1CCCN1C(=O)((C)OC)NC(=O)OC)F)NC(=O)OC)OC
InChI InChI=1S/C57H65F5N10O8/c1-29(77-3)49(67-56(75)79-5)54(73)70-19-7-9-47(70)52-63-41-25-35(37(59)27-43(41)65-52)45-15-16-46(72(45)34-23-39(61)51(40(62)24-34)69-21-17-32(18-22-69)31-11-13-33(58)14-12-31)36-26-42-44(28-38(36)60)66-53(64-42)48-10-8-20-71(48)55(74)50(30(2)78-4)68-57(76)80-6/h11-14,23-30,32,45-50H,7-10,15-22H2,1-6H3,(H,63,65)(H,64,66)(H,67,75)(H,68,76)/t29-,30-,45-,46-,47+,48+,49+,50+/m1/s1 Key:VJYSBPDEJWLKKJ-NLIMODCCSA-N

Pibrentasvir is an NS5A inhibitor antiviral agent. In the United States and Europe, it is approved for use with glecaprevir as the combination drug glecaprevir/pibrentasvir (trade name Mavyret in the US and Maviret in the EU) for the treatment of hepatitis C. It is sold by Abbvie.

References

Ng TI, Krishnan P, Pilot-Matias T, Kati W, Schnell G, Beyer J, et al. (May 2017). "In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir". Antimicrobial Agents and Chemotherapy. 61 (5): e02558–16. doi:10.1128/AAC.02558-16. PMC 5404558. PMID 28193664.
Johnson LA (August 3, 2017). "FDA OKs new drug to treat all forms of hepatitis C". Fox Business.
"Maviret: EPAR – Summary for the public" (PDF). European Medicines Agency. 2017-08-17. Archived from the original (PDF) on 2017-10-19. Retrieved 2017-10-19.

RNA virus antivirals (primarily J05, also S01AD and D06BB)

Hepatitis C

NS3/4A protease inhibitors (–previr)	Asunaprevir Boceprevir Ciluprevir Danoprevir Faldaprevir Glecaprevir Grazoprevir Narlaprevir Paritaprevir Simeprevir Sovaprevir Telaprevir Vaniprevir Vedroprevir Voxilaprevir
NS5A inhibitors (–asvir)	Coblopasvir Daclatasvir Elbasvir Ledipasvir Odalasvir Ombitasvir Pibrentasvir Ravidasvir Ruzasvir Samatasvir Velpatasvir
NS5B RNA polymerase inhibitors (–buvir)	Beclabuvir Bemnifosbuvir Dasabuvir Deleobuvir Filibuvir GS-6620 IDX-184 Setrobuvir Sofosbuvir Tegobuvir TMC-647055 Radalbuvir Uprifosbuvir
Combination drugs	Elbasvir/grazoprevir Glecaprevir/pibrentasvir Ledipasvir/sofosbuvir Ombitasvir/paritaprevir/ritonavir Sofosbuvir/daclatasvir Sofosbuvir/velpatasvir Sofosbuvir/velpatasvir/voxilaprevir

Hepatitis D

Bulevirtide

Picornavirus

viral entry: Pleconaril

Anti-influenza agents

Multiple/general

Interferon	Interferon alfa 2b Peginterferon alfa-2a Peginterferon alfa-2b
3CL protease inhibitors (–trelvir)	Ensitrelvir Ibuzatrelvir Lufotrelvir Nirmatrelvir (+ritonavir) Rupintrivir Simnotrelvir (+ritonavir)
RNA pol inhibitors	CMX521 Deuremidevir Favipiravir Galidesivir GS-441524 Remdesivir MK-608 Mericitabine Molnupiravir NITD008 Ribavirin Taribavirin Triazavirin Valopicitabine
Multiple/Unknown/Other	EICAR Merimepodib Moroxydine Presatovir

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: